$RANI News
Last published 3d ago
- 3d agoRANIRani Therapeutics Holdings, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 3d agoRANIRani Therapeutics Reports Third Quarter 2026 Financial Results; Provides Corporate UpdateGlobeNewswire~ Accepted into the U.S. FDA’s Emerging Technology Program (ETP), enabling early FDA engagement to support development of the RaniPill ® platform technology ~
- 3d agoRANIRani Therapeutics Reports Third Quarter 2026 Financial Results; Provides Corporate UpdateGlobeNewswire~ Accepted into the U.S. FDA’s Emerging Technology Program (ETP), enabling early FDA engagement to support development of the RaniPill® platform technology ~ ~ Enrollment continues in RT-114 Phase 1a expansion cohort;
- 3w agoRANIFireside Chat: Beyond the Needle: Oral, Intranasal & AI-Driven Drug Delivery Platforms - RANI THERAPEUTICS HOLDINGS INCEarnings Call TranscriptsAll right, great. I know we're all coming off lunch in the panel here, so I hope everyone can get settled down now. I'm excited to welcome the team from Ronnie. We have Talat Imran, CEO, here joining us. Kate McKinley. K
- 1mo agoRANIRani Therapeutics to Participate in the Chardan Healthcare ConferenceGlobeNewswireSAN JOSE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s
- 2mo agoRANIRani Therapeutics to Participate in Upcoming September ConferencesGlobeNewswireSAN JOSE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s
- 3mo agoRANIRani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate UpdateGlobeNewswire~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~ ~ Announced positive initial Phase 1a data for RT-114, with oral
- 3mo agoRANICG 46TH ANNUAL GROWTH CONFERENCE - RANI THERAPEUTICS HOLDINGS INCEarnings Call TranscriptsHi, good afternoon, everyone. My name is Edward Nash, Senior Biotech Analyst here at Canaccord Jaduity. I have the pleasure of having Ronnie Therapeutics with us this afternoon. From Ronnie is Talat Emrin, who is the com
- 3mo agoRANICG 46TH ANNUAL GROWTH CONFERENCE - RANI THERAPEUTICS HOLDINGS INCEarnings Call TranscriptsHi, good afternoon, everyone. My name is Edward Nash, Senior Biotech Analyst here at Canaccord Jaduity. I have the pleasure of having Ronnie Therapeutics with us this afternoon. From Ronnie is Talat Emrin, who is the com
- 3mo agoRANIRani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth ConferenceGlobeNewswireSAN JOSE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s
- 3mo agoRANIRani Therapeutics Appoints Michelle Gilson to Board of DirectorsGlobeNewswireSAN JOSE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced the appointment of
- 3mo agoRANIRani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics"; "Rani" or the "Company") (NASDAQ:RANI), a clinical-stage biotherapeutics company
- 4mo agoRANIRani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous DosingGlobeNewswireRT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild and consistent with
- 4mo agoRANIRani Therapeutics Appoints Nicholas Maestas as Chief Financial OfficerGlobeNewswireSAN JOSE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics"; "Rani" or the "Company") (NASDAQ:RANI), a clinical-stage biotherapeutics company
- 5mo agoRANIRani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq RulesGlobeNewswireSAN JOSE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and
- 6mo agoRANIRani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO TransitionGlobeNewswire- Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with ProGen – - Appointed Alireza Javadi, Ph.D. as Chief Technical Officer - - Appointed
- 6mo agoRANIRani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor ConferenceGlobeNewswireSAN JOSE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and
- 7mo agoRANIRani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical StrategyGlobeNewswireSAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics
- 7mo agoRANIRani Therapeutics Fourth Quarter and Full Year 2025 Financial Results Conference CallRANI THERAPEUTICS HOLDINGS INCEarnings Call TranscriptsWelcome to the Rainey fourth quarter and full year 2025 financial results and corporate update conference call. At this time, all participants are on a listen-only mode. Following manager's prepared remarks, Rainey will
- 7mo agoRANIRani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate UpdateGlobeNewswire- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation
- 7mo agoRANIRani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline PrioritizationGlobeNewswireSAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics
- 9mo agoRANIRani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical OfficerGlobeNewswireSAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and
- 10mo agoRANIRani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGenGlobeNewswire- A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, administered orally via RaniPill® capsule versus subcutaneous injection -
- 11mo agoRANIRani Therapeutics to Participate in the Evercore Healthcare ConferenceGlobeNewswireSAN JOSE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and
- 1y agoRANIRani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate UpdateGlobeNewswire– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics – – Completed $60.3 million oversubscribed private placement led by Samsara BioCapital with
- 1y agoRANIRani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025GlobeNewswireSAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and
- 1y agoRANIRani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of DirectorsGlobeNewswireSAN JOSE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics
- 1y agoRANIRani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq RulesGlobeNewswireFinancing led by Samsara BioCapital, L.P. ("Samsara") with participation from additional investors, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mr. Mir Imran Each of Samsara and Anomaly
- 1y agoRANIRani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq RulesGlobeNewswireFinancing led by Samsara BioCapital, L.P. ("Samsara") with participation from additional investors, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mr. Mir ImranAt the closing of the
- 1y agoRANIRani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million FinancingGlobeNewswireRani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit royalties on product
- 1y agoRANIRani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate UpdateGlobeNewswire– Announced strategic research collaboration with Chugai for two undisclosed molecules – – Presented preclinical data demonstrating bioequivalence of novel, bispecific GLP-1/GLP-2 receptor agonist delivered orally
- 1y agoRANIRani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct OfferingGlobeNewswireSAN JOSE, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and
- 1y agoRANIRani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous DeliveryGlobeNewswireSAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and
- 1y agoRANIRani Therapeutics Announces Research Agreement with ChugaiGlobeNewswire- Research agreement is evaluating feasibility of applying Rani's oral delivery technology to Chugai's antibodies against undisclosed targets - SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics
- 1y agoRANIRani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate UpdateGlobeNewswire- Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - -
- 1y agoRANIRani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate UpdateGlobeNewswire- Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 - - Announced
- 1y agoRANIRani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102GlobeNewswire- RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalence – - Both groups demonstrated
- 1y agoRANIRani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireSAN JOSE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics
- 1y agoRANIRani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HCGlobeNewswire- Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and weight loss to subcutaneous administration - - RT-116 was well tolerated with no serious
- 1y agoRANIRani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate UpdateGlobeNewswire- Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 - - Announced new preclinical pharmacokinetic data supporting transenteric delivery of
- 2y agoRANIRani Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireSAN JOSE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and
- 2y agoRANIRani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin TriagonistGlobeNewswire-Transenteric delivery of incretin triagonist GLP-1, GIP, glucagon receptors mimicking the RaniPill route of administration elicits rapid weight loss and bioavailability comparable to subcutaneous injection - - New
- 2y agoRANIRani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing WarrantsGlobeNewswireSAN JOSE, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and
- 2y agoRANIRani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual SummitGlobeNewswireSAN JOSE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics
- 2y agoRANIRani Therapeutics to Participate in September Investor ConferencesGlobeNewswireSAN JOSE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics
- 2y agoRANIRani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate UpdateGlobeNewswire- Announced partnership with ProGen on development of RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity - - Phase 1 study for RT-114 expected to initiate in 2025 - - Completed equity offering with
- 2y agoRANIRani Therapeutics to Participate in August Investor ConferencesGlobeNewswireSAN JOSE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and
- 2y agoRANIRani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct OfferingGlobeNewswireSAN JOSE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and
- 2y agoRANIRani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity TreatmentGlobeNewswire~ New RT-114 obesity program combines ProGen's FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with
- 2y agoRANIRani Therapeutics to Participate in May Investor ConferencesGlobeNewswireSAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and